Degree of Cyclooxygenase-2 Inhibition Modulates Blood Pressure Response to Celecoxib and Naproxen.
Katherine N ThekenSoumita GhoshCarsten SkarkeSusanne FriesNicholas F LahensDimitra SarantopoulouGregory R GrantGarret A FitzGeraldTilo GrosserPublished in: medRxiv : the preprint server for health sciences (2024)
Celecoxib 200 mg/day inhibited COX-2 activity to a lesser degree than naproxen 500 mg/day, resulting in a less pronounced blood pressure increase. While the PRECISION trial concluded the non-inferiority of celecoxib regarding cardiovascular risk, this is based on a comparison of doses that are not equipotent.ClinicalTrials.gov identifier: NCT02502006 (https://clinicaltrials.gov/study/NCT02502006).